Jouvent R, Le Houezec J, Payan C, Mikkelsen H, Fermanian J, Millet V, Dufour H
CNRS URA 1957, Pavillon Clérambault, Hôpital de la Salpêtrière, Paris, France.
Psychiatry Res. 1998 Jul 13;79(3):267-75. doi: 10.1016/s0165-1781(98)00046-8.
The onset of action (during the first 2 weeks of treatment) of moclobemide (450 mg/day), a reversible MAO-A inhibitor, was compared in a double-blind, multi-center trial with clomipramine (150 mg/day) on dimensional and global depressive symptoms in 124 hospitalized patients suffering from a major depressive episode according to DSM-III-R criteria and with blunted affect and retardation. An earlier efficacy was found for moclobemide with significant treatment differences in favor of moclobemide, which were detected on negative symptoms (anhedonia, blunted affect and retardation) on days 7 and 10. The overall effect on depression at the end of the 4-week trial period was similar in both groups. However, a higher termination rate due to lack of efficacy was found with moclobemide (10 vs. 3). The tolerability was significantly better for moclobemide, as shown by the lower frequency of adverse events.
在一项双盲、多中心试验中，对124例符合DSM-III-R标准、存在情感迟钝和迟缓的重度抑郁发作住院患者，比较了可逆性单胺氧化酶-A抑制剂吗氯贝胺（450毫克/天）和氯米帕明（150毫克/天）在治疗的前两周的起效情况，以及对维度和整体抑郁症状的影响。结果发现吗氯贝胺起效更早，在第7天和第10天的阴性症状（快感缺失、情感迟钝和迟缓）方面存在有利于吗氯贝胺的显著治疗差异。在4周试验期结束时，两组对抑郁的总体疗效相似。然而，吗氯贝胺因疗效不佳导致的停药率更高（10例 vs. 3例）。吗氯贝胺的耐受性明显更好，不良事件发生率更低。
